Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Y mAbs Therapeutics : mAbs Announces Priorit Review of BLA for DANELZA (naxitamab-gqgk) in China

09/14/2021 | 10:39am EDT

NEW YORK - Y-mAbs Therapeutics, Inc. ('Y-mAbs' or the 'Company'), NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced that its partner SciClone Pharmaceuticals (Holdings) Limited ('SciClone Pharmaceuticals') has been granted priority review of the Biologics License Application ('BLA') for DANYELZA (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma by the Center for Drug Evaluation ('CDE') of China'sNational Medical Products Administration ('NMPA').

'We are pleased to see SciClone Pharmaceuticals receive priority review of the DANYELZA BLA in China. Priority review in China is intended to expedite review and approval, which means that we could potentially be facing approval and launch of DANYELZA in China as soon as the first quarter of 2022,' commented Thomas Gad, founder, Chairman and President at Y-mAbs.

Dr. Claus Moller, Chief Executive Officer, continued, 'DANYELZA was recently prescribed for the first time in China, and we were excited to learn that the first patient had received treatment at the Lecheng Branch of Hainan Women and Children's Medical Center in Hainan Boao Lecheng International Medical Tourism Pilot Zone.'

Researchers at MSK developed DANYELZA, which is exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the product.

About DANYELZA (naxitamab-gqgk)

DANYELZA (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor ('GM-CSF'), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication was approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. DANYELZA includes a Boxed Warning for serious infusion-related reactions, such as cardiac arrest and anaphylaxis, and neurotoxicity, such as severe neuropathic pain and transverse myelitis. See full Prescribing Information for complete Boxed Warning and other important safety information.

About Y-mAbs

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our business model and development, commercialization and product distribution plans; current and future clinical and pre-clinical studies and our research and development programs; expectations related to the timing of the initiation and completion of regulatory submissions; regulatory, marketing and reimbursement approvals; rate and degree of market acceptance and clinical utility as well as pricing and reimbursement levels; retaining and hiring key employees; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position and strategy; additional product candidates and technologies; collaborations or strategic partnerships and the potential benefits thereof; expectations related to the use of our cash and cash equivalents, and the need for, timing and amount of any future financing transaction; our financial performance, including our estimates regarding revenues, expenses, capital expenditure requirements; developments relating to our competitors and our industry; and other statements that are not historical facts. Words such as ''anticipate,'' ''believe,'' 'contemplate,' ''continue,'' ''could,'' ''estimate,'' ''expect,'' 'hope,' ''intend,'' ''may,'' ''might,'' ''plan,'' ''potential,'' ''predict,'' ''project,'' ''should,'' ''target,'' 'will', ''would'' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with our financial condition and need for additional capital; risks associated with our development work; cost and success of our product development activities and clinical trials; the risks of delay in the timing of our regulatory submissions or failure to receive approval of our drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of our product candidates; development of our sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for our products; the risks related to our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; the risks related to government regulation; risks related to market approval, risks associated with protection of our intellectual property rights; risks related to employee matters and managing growth; risks related to our common stock, risks associated with the pandemic caused by the coronavirus known as COVID-19, including the emergence of variants such as the Delta variant, and other risks and uncertainties affecting the Company including those described in the 'Risk Factors' section included in our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC and in our other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

'DANYELZA' and 'Y-mAbs' are registered trademarks of Y-mAbs Therapeutics, Inc.

Contact:

Y-mAbs Therapeutics, Inc.

230 Park Avenue

Suite 3350

New York, NY 10169

USA

T: +1 646 885 8505

E-mail: info@ymabs.com

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED 2.19% 11.18 End-of-day quote.0.00%
Y-MABS THERAPEUTICS, INC. 1.07% 26.55 Delayed Quote.-46.37%
All news about Y-MABS THERAPEUTICS, INC.
10/19INSIDER SELL : Y-mabs Therapeutics
MT
10/08Y MABS THERAPEUTICS : mAbs 177Lu-omburtamab-DTPA for the Treatment of Patients with Medull..
AQ
10/07Y MABS THERAPEUTICS : Gets FDA's Rare Pediatric Disease Designation for Potential Therapy ..
MT
10/07Y MABS THERAPEUTICS : mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medul..
PU
10/07Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/07Y MABS THERAPEUTICS : mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medul..
AQ
10/07U.S. Food and Drug Administration Grants Rare Pediatric Disease Designation for Y-mAbs’..
CI
10/04INSIDER SELL : Y-mabs Therapeutics
MT
09/23INSIDER SELL : Y-mabs Therapeutics
MT
09/16Y MABS THERAPEUTICS : mAbs Announces Data to be Presented at SIOP 2021
AQ
More news
Analyst Recommendations on Y-MABS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 71,5 M - -
Net income 2021 -42,6 M - -
Net cash 2021 83,9 M - -
P/E ratio 2021 -30,9x
Yield 2021 -
Capitalization 1 157 M 1 157 M -
EV / Sales 2021 15,0x
EV / Sales 2022 6,74x
Nbr of Employees 125
Free-Float 83,7%
Chart Y-MABS THERAPEUTICS, INC.
Duration : Period :
Y-mAbs Therapeutics, Inc. Technical Analysis Chart | YMAB | US9842411095 | MarketScreener
Technical analysis trends Y-MABS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 26,55 $
Average target price 55,33 $
Spread / Average Target 108%
EPS Revisions
Managers and Directors
Claus Juan Møller-San Pedro Chief Executive Officer & Director
Thomas Gad Chairman, President & Head-Business Development
Bo Kruse CFO, Secretary. Treasurer & Executive VP
Torben Lund-Hansen Chief Technology Officer & Senior Vice President
Steen Lisby Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
Y-MABS THERAPEUTICS, INC.-46.37%1 157
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610